| Prev Close | 7.49 |
| Open | 7.45 |
| Day Low/High | 7.33 / 7.56 |
| 52 Wk Low/High | 2.38 / 6.56 |
| Volume | 784.71K |
| Avg Volume | 3.51M |
| Exchange | NASDAQ |
| Shares Outstanding | 170.80M |
| Market Cap | 1.33B |
| EPS | -0.70 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Biotech Movers: Akari, Array, Amicus
Akari Therapeutics, Array BioPharma and Amicus Therapeutics were among the biotech movers in premarket trading on Wednesday.
Bristol-Myers Hookup Boosts Array BioPharma
Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.
Despite Amazon's Stock Hitting $1,000, the Nasdaq Is in Danger of Breaking This Streak
Here's what traders are saying.
Another Drop in Crude Oil Prices Pulls S&P 500 From Records
Crude oil prices continue their decline on Tuesday, pulling the energy sector lower and the S&P 500 from its records achieved last week.
Biotech Movers: Array Shares Rise on Bristol-Myers Collaboration
Array BioPharma, Advaxis, Merrimack Pharmaceuticals and Insys Therapeutics were among the biotech stock movers in premarket trading on Tuesday.
Stock Futures Lower as Traders Return From Long Holiday Weekend
Stock futures point to a lower open on Tuesday as traders return to Wall Street after the long Memorial Day weekend.
Array BioPharma And Bristol-Myers Squibb Announce Strategic Collaboration
Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of...
Array BioPharma And Bristol-Myers Squibb Announce Strategic Collaboration
- Novel combinations of binimetinib, Opdivo® (nivolumab) and Yervoy® (ipilimumab) to be studied in colorectal cancer patients
Biotech Movers: Myriad Genetics, Spectrum Pharmaceuticals, Array BioPharma
Myriad Genetics, Spectrum Pharmaceuticals and Array BioPharma were among the biotech stock movers in early trading on Wednesday.
How Far Into the Drug Pipeline Should the FTC Reach?
Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.
If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss
Here's how to potentially rake in some fat profits off a number of hot breakout setups.
How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More
Here's how to trade six of the most active names on the market this afternoon.
Biotech Premarket Movers: CytomX, Aevi, Esperion
CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.
Array BioPharma Provides NEMO Update
- NRAS-mutant melanoma NDA withdrawn based on thorough discussions with FDA and following late cycle review meeting -
PaylPal, CH Robinson Worldwide, Texas Instruments: 'Mad Money' Lightning Round
Jim Cramer is bullish on PaylPal, CH Robinson Worldwide, Texas Instruments and NXP Semiconductors.
Here's Why Buffett Is So Bullish About This Market: Cramer's 'Mad Money' Recap (Monday 2/27/17)
Jim Cramer highlight's Buffett's confidence in American businesses and stocks, and his critique of high fees charged by money managers.
Analysts' Actions -- Eaton, Ford, Altria, Ralph Lauren and More
Here are Friday's top research calls, including an upgrade for Ford and downgrades for Eaton, Altria and Ralph Lauren.
Analysts' Actions -- Air Products, Disney, Colgate-Palmolive, Noble and More
Here are Monday's top research calls, including downgrades for Air Products and Colgate-Palmolive, and upgrades for Disney and Noble.
Take-Two Interactive and Actvision Blizzard: 'Mad Money' Lightning Round
Jim Cramer thinks Take-Two Interactive and Activision Blizzard have winning potential.
Buy 'Trump Stocks' on Any Market-Induced Weakness: Cramer's 'Mad Money' Recap (Friday 1/20/17)
The idea of buying American and hiring American is good news for defense, ag and energy stocks, says Jim Cramer.
Loxo Oncology Aims for Genetic Mutation Cancer Drug Approval in 2018
The Loxo phase II 'basket' study of larotrectinib is expected to complete patient enrollment in early 2017 and report results in the second half of the year.
'Mad Money' Lightning Round: Jim Cramer Focuses on Airline, Bank Stocks
Alaska Air is 'among the best,' says Jim Cramer; he also likes Southwest.
Jim Cramer's 'Mad Money' Recap: Don't Miss This Rotation Back Into the Nasdaq
How did these technology stocks suddenly get their groove back? asks Jim Cramer.
The Market Offers Some Opportunities but They're Disappearing Fast
The market isn't buying that Trump is bad for business
Take a Chill Pill: If Clinton Wins, Drug-Price Controls Aren't Guaranteed
Such unwarranted fears have depressed the sector, which could bounce back after Nov. 8.
